NasdaqGS:AMRXPharmaceuticals
Is It Too Late To Reassess Amneal Pharmaceuticals (AMRX) After Its 65% One-Year Surge?
Some investors may be wondering if Amneal Pharmaceuticals at around US$12.80 is still reasonably priced after a strong run, or if the easier gains are already behind it.
The stock has recent returns of 1.2% over 7 days, 3.0% over 30 days, 1.1% year to date and 65.4% over the last year, with a very large 3 year gain and a 121.5% return over 5 years.
Recent coverage has focused on Amneal Pharmaceuticals as a generic and specialty pharmaceuticals player, with attention on its role in supplying...